What are biological indicators and why are they required for sterilization validation?

Sterilization in medical/pharmaceutical settings: hospitals sterilize surgical instruments between procedures to kill bacteria, viruses, and other pathogens; medical device manufacturers sterilize packaged devices (catheters, implants, surgical tools) before shipping to hospitals; pharmaceutical manufacturers sterilize production equipment and environments to prevent contamination of sterile injectable drugs; the sterilization methods include autoclaving (steam under pressure — moist heat), ethylene oxide gas (EtO), dry heat, gamma radiation, and electron beam. The validation problem: sterilization processes must achieve a specific 'sterility assurance level' (typically 10⁻⁶ — one chance in a million that a viable microorganism survives); how does a hospital or manufacturer verify that the sterilization cycle actually achieved this level? Physical indicators (time, temperature, pressure monitoring) confirm that the sterilizer operated correctly, but they don't confirm that biological kill actually occurred at the correct level. Biological indicators (BIs): a biological indicator is a standardized test product containing a known quantity of highly resistant bacterial spores (typically Geobacillus stearothermophilus for steam sterilization, or Bacillus atrophaeus for EtO); the BI is placed inside the load being sterilized; after the sterilization cycle, the BI is incubated; if no bacterial growth occurs (the color indicator in the growth medium doesn't change), the sterilization achieved the kill requirement for those specific resistant spores, providing confidence the process worked; if growth occurs (color changes, indicating bacterial survival), the sterilization cycle failed. Regulatory requirement: FDA regulations, United States Pharmacopeia (USP), ISO standards, and AAMI standards require biological indicator testing as part of validated sterilization programs; hospitals must periodically validate sterilizers; medical device manufacturers must validate and routinely monitor sterilization processes; this regulatory mandate creates non-discretionary recurring demand for biological indicators as consumables.

What is equipment calibration and why does the pharmaceutical industry require it?

Measurement accuracy: pharmaceutical manufacturing and quality control require precise measurements — temperature (storage conditions for heat-sensitive drugs), pressure (sterile manufacturing environments), weight (drug dispensing accuracy), pH (chemical reactions), flow rate (manufacturing processes), and hundreds of other parameters; if a measurement instrument drifts from its calibrated setting (due to age, wear, or environmental effects), measurements become inaccurate; inaccurate measurements can lead to incorrect conclusions about product quality. Calibration process: calibration is the process of comparing a measurement instrument's readings against a known reference standard and adjusting or documenting any deviation; a thermometer used to monitor a pharmaceutical refrigerator is calibrated by comparing it against a NIST-traceable reference thermometer in a controlled temperature environment; if the thermometer reads 0.5°C too high, the calibration record documents this offset; the instrument is either adjusted (if adjustable) or the offset is noted for correction in measurement records. FDA cGMP requirement: FDA's Current Good Manufacturing Practice (cGMP) regulations for pharmaceutical manufacturing (21 CFR Parts 210 and 211) explicitly require pharmaceutical manufacturers to calibrate instruments used in production and quality control at defined intervals; calibration records must be maintained and available for FDA inspection; failure to maintain adequate calibration programs is a common FDA 483 observation (a written observation of regulatory non-compliance); pharmaceutical companies that fail FDA inspections risk production shutdown or drug recall. Calibration service market: pharmaceutical manufacturers either operate internal calibration labs or outsource calibration services to specialized providers like Mesa Labs; calibration requires specialized knowledge, reference standards traceable to NIST (the National Institute of Standards and Technology), and documentation systems meeting FDA audit requirements; many pharmaceutical companies prefer outsourcing calibration to specialists rather than maintaining complex internal calibration systems.

How does Mesa Labs grow through acquisitions and what does it look for in targets?

Acquisition strategy: Mesa Labs has grown from a single-product measurement company to a diversified quality compliance platform through acquisitions of businesses in adjacent regulatory compliance niches; Mesa targets companies that: serve regulated industries (pharmaceutical, medical device, food safety) where compliance requirements create non-discretionary demand; have recurring revenue from consumables or services (not one-time capital equipment sales); are profitable but small enough to be uninteresting to large industrial companies; have defensible niche positions (market leaders in a specific type of calibration or compliance testing); and are valued at reasonable acquisition multiples. Example acquisitions: Bios International (gas flow measurement and calibration); Sifam Tinsley (UK precision measurement instruments); Temprime (temperature data logging for pharmaceutical cold chain) — each acquisition added a new compliance niche to Mesa's portfolio; Mesa looks for businesses that can cross-sell to each other's regulated industry customer base. Integration approach: Mesa typically acquires, maintains the acquired brand and product lines (customers of niche compliance products expect continuity), and integrates back-office functions (finance, HR, IT) to capture cost synergies; Mesa's holding company model (similar to Roper Technologies or HEICO) maintains separate business units under centralized financial oversight. Organic vs. inorganic balance: Mesa's challenge is balancing acquisition pace with integration quality; each acquisition requires management attention for integration; if Mesa acquires too aggressively, integration quality declines and the acquired businesses underperform; Mesa's management track record in integrating niche compliance businesses while maintaining product quality and customer relationships is the primary execution risk investors evaluate.

Data as of: September 20, 2026

brimindinvest.com / compare / kn-vs-mlabLIVE

KN

Knowles Corporation · Technology - MEMS Microphones and Audio Acoustics Components

$35.55

+2.18% this month

VERSUS

COMPARE

MLAB

Mesa Labs, Inc. · Healthcare/Industrials - Laboratory Measurement, Calibration, and Quality Compliance

$126.54

+5.83% this month

Comparison scoreboard

KN LEADS 3/5

AI Scorei

KN ✓42.9

MLAB 34.3

1Y Returni

KN +56.06%

MLAB ✓+84.13%

Fwd P/Ei

KN 21.94

MLAB ✓12.72

Target Up.i

KN ✓+23.27%

MLAB -10.07%

Op. Margini

KN ✓15.17%

MLAB 11.69%

Metrics last refreshed: 9/20/2026

Quick take

KN vs MLAB Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

KN (Knowles Corporation) and MLAB (Mesa Labs) are both specialty technology component companies in distinct niches — Knowles is the global MEMS microphone market leader serving smartphones, hearing aids, and voice-interface devices with semiconductor-precision acoustic technology, while Mesa Labs is a quality compliance measurement and calibration company serving pharmaceutical, medical, and industrial regulated industry requirements through calibration services, biological indicators, and data integrity solutions.

KN vs MLAB is MEMS microphone technology leader with consumer electronics and hearing health exposure (Knowles's global microphone manufacturing leadership, hearing aid acoustic heritage, and voice interface proliferation tailwind — smartphone cyclicality, Infineon/AAC competition, and Apple concentration risk) versus niche laboratory calibration and sterilization compliance provider with recurring consumable demand (Mesa Labs's regulatory mandate-driven calibration services, biological indicator consumables, and acquisition-driven diversification — integration complexity, clinical genomics normalization, and small-cap liquidity).

Live analysis · updated 9/20/2026

KN holds the edge across 3 of 5 key metrics in this comparison. MLAB leads on both 1-year return (+84.13%) and forward P/E quality (12.72x vs 21.94x for KN), a relatively favorable combination of momentum and valuation. KN leads on both revenue growth (14.30%) and operating margin (15.17%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for KN (+23.27%) than for MLAB (-10.07%).

Normalized 1Y performance

KN

MLAB

Recent returns

KN

MLAB

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

KN

Price target range

analyst mean$43.75
current price$35.55

+23.3% upside to analyst mean

MLAB

Price target range

analyst mean$117.50
current price$126.54

-10.1% upside to analyst mean

Who should consider this stock?

KN may suit investors who:

Want semiconductor component exposure through MEMS microphone technology leadership with multi-decade manufacturing expertise serving smartphones, hearing aids, and voice-interface devices
Value Knowles's dual exposure to cyclical consumer electronics (smartphone microphones) and more stable hearing health demographics (hearing aid acoustic components for aging global population)
Believe voice interface proliferation (smart speakers, smartphone voice assistants, hearables) increases microphone count per device and creates new high-value audio applications for Knowles's technology

MLAB may suit investors who:

Want quality compliance measurement exposure through the recurring demand of pharmaceutical and hospital calibration and sterilization validation requirements that cannot be deferred under FDA and USP regulations
Value Mesa Labs's biological indicator consumables as a recurring revenue model where every sterilization cycle uses disposable biological test products — creating predictable non-discretionary demand
Accept acquisition integration complexity for Mesa Labs's strategy of consolidating niche quality compliance measurement businesses that individually are too small for larger industrial companies to pursue

Performance & AI score

Performance & AI score
Metric	KN	MLAB
AI scorei	42.9	34.3
AI ranki	#903	#1868
Latest closei	$35.55	$126.54
1M returni	+2.18%	+5.83%
6M returni	+46.90%	+58.62%
1Y returni	+56.06%	+84.13%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

$10,000 invested — hypothetical growth (dividends reinvested)
Period	KN	MLAB
1Y ago	$15.61K (+56.1%) started 2025-09-18	$18.53K (+85.3%) started 2025-09-18
5Y ago	$19.2K (+92.0%) started 2021-09-20	$4.21K (-57.9%) started 2021-09-20
10Y ago	$24.74K (+147.4%) started 2016-09-19	$12.21K (+22.1%) started 2016-09-19

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Valuation & upside potential
Metric	KN	MLAB
Market capi	$3.03B	$731.1M
Trailing P/Ei	42.25	153.71
Forward P/Ei	21.94	12.72
Price/Salesi	N/A	N/A
EV/Revenuei	4.93	3.33
Analyst targeti	$43.75	$117.50
Target upsidei	+23.27%	-10.07%

Growth, profitability & risk

Growth, profitability & risk
Metric	KN	MLAB
Revenue growthi	14.30%	1.00%
Earnings growthi	146.60%	-42.40%
EPS growthi	+146.60%	-42.40%
FCF margini	+6.19%	+21.38%
Operating margini	15.17%	11.69%
Profit margini	10.63%	1.92%
ROIC proxyi	9.50%	2.66%
Return on equityi	9.50%	2.66%
Dividend yieldi	N/A	0.51%
Payout ratioi	0.00%	75.29%
Dividend growth streaki	N/A	No increase yet
Betai	1.59	0.93
Debt/equityi	18.88	85.48
Current ratioi	3.20	1.79
Quick ratioi	1.64	1.16

Correlation

Over the past year, KN and MLAB have moved weakly in the same direction (correlation of 0.16), based on daily returns.

1Y

0.16

-1.0+1.0

5Y

0.36

-1.0+1.0

10Y

0.31

-1.0+1.0

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

KN max drawdowni23.83%

MLAB max drawdowni24.17%

KN max wkly dropi16.39%

MLAB max wkly dropi19.84%

5Y risk snapshot

KN max drawdowni49.55%

MLAB max drawdowni82.43%

KN max wkly dropi18.03%

MLAB max wkly dropi25.19%

10Y risk snapshot

KN max drawdowni49.55%

MLAB max drawdowni82.43%

KN max wkly dropi22.74%

MLAB max wkly dropi26.36%

Performance metrics by period

Performance metrics by period
Period	Metric	KN	MLAB
1Y	Growthi	+56.06%	+84.13%
	CAGRi	+56.11%	+84.20%
	Volatilityi	40.08%	54.28%
	Sharpe ratioi	1.20	1.32
	Sortino ratioi	1.77	2.00
	Max drawdowni	23.83%	24.17%
	Current drawdowni	16.94%	3.15%
	Avg drawdowni	6.94%	5.45%
	Ulcer Indexi	9.27%	7.35%
	Max daily dropi	9.21%	16.49%
	Max wkly dropi	16.39%	19.84%
5Y	Growthi	+91.95%	-58.97%
	CAGRi	+13.95%	-16.34%
	Volatilityi	34.81%	50.50%
	Sharpe ratioi	0.42	-0.19
	Sortino ratioi	0.63	-0.26
	Max drawdowni	49.55%	82.43%
	Current drawdowni	16.94%	60.96%
	Avg drawdowni	20.98%	56.41%
	Ulcer Indexi	24.41%	59.82%
	Max daily dropi	14.69%	24.92%
	Max wkly dropi	18.03%	25.19%
10Y	Growthi	+147.39%	+16.87%
	CAGRi	+9.48%	+1.57%
	Volatilityi	34.58%	43.82%
	Sharpe ratioi	0.31	0.16
	Sortino ratioi	0.44	0.22
	Max drawdowni	49.55%	82.43%
	Current drawdowni	16.94%	60.96%
	Avg drawdowni	19.17%	32.92%
	Ulcer Indexi	22.56%	43.06%
	Max daily dropi	19.56%	25.72%
	Max wkly dropi	22.74%	26.36%

AI Prediction Signali

Members only

Next 5 trading days

+2.8%BUY

MLAB

+1.1%HOLD

Next 30 trading days

+6.4%BUY

MLAB

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	KN	MLAB
Company	Knowles Corporation	Mesa Labs, Inc.
Sector	Technology	Technology
Industry	Electronic Components	Scientific & Technical Instruments
Core business	Knowles Corporation is the world's largest manufacturer of MEMS (microelectromechanical systems) microphones — tiny silicon-based microphones used in smartphones, hearables (AirPods, wireless earbuds), hearing aids, smart speakers, and IoT devices. Knowles's miniaturized MEMS microphone technology converts sound waves to electrical signals with high sensitivity and low power consumption in an extremely small package suitable for modern consumer electronics. Knowles also provides precision audio processing ICs, balanced armature speakers for hearing aids and in-ear monitors, and acoustic solutions. Knowles serves Apple, Samsung, and other major smartphone OEMs, as well as hearing aid companies (Sonova, WS Audiology, Starkey). Knowles has been a market leader in hearing aid acoustic components for over 60 years.	Mesa Labs provides critical measurement, calibration, testing, and data integrity solutions for regulated industries including pharmaceuticals, medical devices, food and beverage, and industrial applications. Mesa's business segments include: Calibration Solutions (providing calibration of test and measurement equipment for pharmaceutical and industrial quality systems — validating that temperature sensors, pressure gauges, pipettes, and other instruments measure accurately); Sterilization and Disinfection Control (biological indicators for validating sterilization processes in hospitals and medical device manufacturers — small biological test indicators that verify sterilization cycles killed all bacteria); Clinical Genomics (Bios International, acquired, providing controls for clinical PCR testing); and Data Integrity (Validatek/Temprime — providing data logging and environmental monitoring for GDP/GMP compliance in pharmaceutical cold chain). Mesa Labs has grown primarily through acquisitions of niche measurement and compliance businesses.
Investor focus	Investors track Knowles's revenue by market (consumer electronics vs. hearing health vs. precision devices), MEMS microphone market share, content per device (number of microphones per smartphone increasing with voice assistant features), and margin improvement from product mix shift toward higher-value audio solutions.	Investors track Mesa Labs's organic revenue growth across segments, EBITDA margin, acquisition integration progress, and the recurring nature of calibration and compliance consumable revenue.

KN strengths

MEMS microphone market leadership with multi-decade manufacturing expertise creates a significant barrier to entry — producing high-quality MEMS microphones requires precision semiconductor fabrication expertise; Knowles has refined its process over decades; new entrants face long development timelines to reach comparable performance
Hearing health market provides stable, non-cyclical revenue from an aging global population with increasing hearing loss prevalence — hearing aid demand grows with demographics; hearing aid acoustic components are long-term relationships with hearing device OEMs
Voice interface proliferation (Amazon Echo, Apple HomePod, Google Nest, and smartphone voice assistants) increases microphone count per device and creates new use cases for high-quality MEMS microphones

MLAB strengths

Calibration and sterilization validation are regulatory requirements — pharmaceutical manufacturers and hospitals must validate their equipment and sterilization processes under FDA/USP/cGMP regulations; this regulatory mandate creates non-discretionary, recurring demand for Mesa's calibration services and biological indicators
Biological indicators are consumables with recurring demand — each sterilization cycle in a hospital or medical device company requires using a biological indicator (a disposable product with live bacterial spores); this consumable model provides recurring revenue independent of capital equipment cycles
Niche market leadership in specialized compliance niches reduces competition — Mesa Labs's calibration solutions and biological indicator businesses serve specialized regulatory compliance needs that mainstream industrial companies find unattractive due to the regulatory complexity and small market sizes

Risks to watch — KN

Smartphone market cyclicality creates revenue volatility — MEMS microphone volumes are highly tied to smartphone production; when smartphone sales decline (as in 2022-2023), Knowles's consumer revenue falls accordingly
Competition from Infineon, AAC Technologies, and other MEMS microphone manufacturers — the MEMS microphone market has multiple capable competitors; Knowles maintains leadership through performance advantage but faces pricing pressure in commodity microphone tiers
Apple customer concentration risk — Apple is likely Knowles's largest customer; any design win loss or Apple production volume decline has significant impact on Knowles's financials

Risks to watch — MLAB

Acquisition-driven growth strategy requires effective integration — Mesa has grown through multiple acquisitions; integrating acquired businesses (systems, culture, products) while sustaining organic growth is operationally complex
Clinical genomics segment integration and diagnostics market cyclicality — Mesa's clinical genomics controls business serves the PCR testing market, which experienced COVID-driven surge then normalization; managing a diagnostics business requires different expertise than calibration
Small-cap liquidity risk — Mesa Labs's market capitalization makes it a smaller, less liquid stock that institutional investors may overlook; liquidity constraints affect bid-ask spreads and the stock's ability to reflect fair value

Frequently asked questions

Traditional electret condenser microphones: before MEMS, most consumer electronics used electret condenser microphones (ECMs) — components containing a diaphragm, backplate, and electret material that generates charge; ECMs are relatively large, sensitive to vibration, and difficult to miniaturize below certain sizes while maintaining performance. MEMS microphone technology: MEMS (microelectromechanical systems) microphones are fabricated using semiconductor photolithography processes on silicon wafers — the same manufacturing techniques used to make computer chips; the MEMS microphone contains a tiny vibrating silicon diaphragm and a backplate separated by a small air gap; sound pressure moves the diaphragm, changing the capacitance between the diaphragm and backplate; an application-specific integrated circuit (ASIC) converts this capacitance change to an electrical signal. Why MEMS wins: extreme miniaturization (MEMS microphones can be as small as 2.5 x 1.8 x 0.9mm); high signal-to-noise ratio (clean audio capture even in small packages); high reliability (semiconductor fabrication consistency vs. hand-assembled ECMs); heat resistance (survives solder reflow temperatures, enabling automated PCB assembly); directional arrays (multiple MEMS microphones can be combined in arrays for beamforming — focusing on the speaker's direction and rejecting background noise). Smartphone application: modern smartphones use 4-6 MEMS microphones placed at different locations on the device (bottom, top, back); multiple microphones enable: noise cancellation (the phone compares signals from multiple microphones to identify and subtract ambient noise); voice isolation (focusing on the speaker's voice while rejecting environmental noise); immersive recording (capturing spatial audio for video); voice wake (always-listening microphones tuned for low-power voice activation). Hearing aid application: hearing aids require the smallest, most power-efficient, highest-quality microphones possible (hearing aids are worn in the ear canal or behind the ear and run on tiny batteries); Knowles's heritage in miniature hearing aid acoustic components predates its smartphone business.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

More comparisons